dopaview 222 mbq/ml inj. sol. i.v. vial
advanced accelerator applications - fluorodopa (18 f) 222 mbq/ml - solution for injection - 222 mbq/ml - fluorodopa (f-18) 222 mbq/ml - fluorodopa (18f)
fluorodopa 18f cis bio international 90 mbq/ml inj. sol. i.v. vial
cis bio international - fluorodopa (18 f) 90 mbq/ml - solution for injection - 90 mbq/ml - fluorodopa (f-18) - fluorodopa (18f)
dopacis 90 mbq/ml solution for injection
cis bio international route nationale 306-saclay, bp 32, 91192, gif-sur-yvette cedex, france - fluorodopa - solution for injection - fluorodopa (18f) 90 mbq/ml - diagnostic radiopharmaceuticals
fluorodopa f18 injection
the feinstein institutes for medical research - fluorodopa f-18 (unii: 2c598205qx) (fluorodopa f-18 - unii:2c598205qx) - fluorodopa f 18 injection is indicated for use in positron emission tomography (pet) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected parkinsonian syndromes (ps). fluorodopa f 18 pet is an adjunct to other diagnostic evaluations. none risk summary there are no available data on fluorodopa f 18 injection use in pregnant women. additionally, animal reproductive and developmental toxicity studies have not been conducted with fluorodopa f 18 injection. however, all radiopharmaceuticals, including fluorodopa f 18 injection, have a potential to cause fetal harm depending on the stage of fetal development, and the magnitude of the radiation dose. if considering fluorodopa f 18 injection administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from the drug and the gestational timing of exposure. the estimated background risk of major birth defects and miscarriage for the indica
fluorodopa f18 injection
the feinstein institutes for medical research - fluorodopa f-18 (unii: 2c598205qx) (fluorodopa f-18 - unii:2c598205qx) - fluorodopa f 18 injection is indicated for use in positron emission tomography (pet) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected parkinsonian syndromes (ps). fluorodopa f 18 pet is an adjunct to other diagnostic evaluations. none risk summary there are no available data on fluorodopa f 18 injection use in pregnant women. additionally, animal reproductive and developmental toxicity studies have not been conducted with fluorodopa f 18 injection. however, all radiopharmaceuticals, including fluorodopa f 18 injection, have a potential to cause fetal harm depending on the stage of fetal development, and the magnitude of the radiation dose. if considering fluorodopa f 18 injection administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from the drug and the gestational timing of exposure. the estimated background risk of major birth defects and miscarriage for the indica
dopaview 222 mbq/ml injektionslösung
dopacis 90 mbq/ml solution for injection
cis bio international - fluorodopa (18 f) - solution for injection - 90 mbq/ml - other diagnostic radiopharmaceuticals for tumour detection
teva-entacapone tablet
teva canada limited - entacapone - tablet - 200mg - entacapone 200mg - catechol-o-methyltransferase (comt) inhibitors
comtan tablet
sandoz canada incorporated - entacapone - tablet - 200mg - entacapone 200mg - catechol-o-methyltransferase (comt) inhibitors
stalevo tablet
sandoz canada incorporated - levodopa; carbidopa; entacapone - tablet - 50mg; 12.5mg; 200mg - levodopa 50mg; carbidopa 12.5mg; entacapone 200mg - catechol-o-methyltransferase (comt) inhibitors